Chronic Endometritis, Uterine Natural Killer Level and Celiac Disease Predisposition in Idiopathic Recurrent Pregnancy Loss
American Journal of Reproductive Immunology · 2026-09 · 96 (3)
DOI: 10.1111/aji.70323 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift American Journal of Reproductive Immunology, online erschienen am 23.09.2026. Verfasst von Inversetti Annalisa und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Humanitas University, Milan, Italy. Hauptthemen laut MEDLINE: Abortion, Habitual, Killer Cells, Natural, Celiac Disease, Endometritis. Die Arbeit nennt 50 Literaturangaben.
Abstract (Originalsprache)
Objective
Both chronic endometritis (CE) and high levels of uterine Natural Killer (uNK) have been associated to recurrent pregnancy loss (RPL), but a clear causality has not yet been defined. In addition, an increased prevalence of celiac disease (CD) genetic predisposition, defined by HLA‐DQ2/DQ8 high risk, has been reported in RPL patients, despite negative serological screening for CD. Recent evidence suggested that HLA‐mediated immune mechanisms may contribute to endometrial inflammation. The two main aims of this multicenter retrospective cohort study were to assess the prevalence of CE and high uNK cells level in idiopathic RPL patients with and without HLA‐DQ2/DQ8 haplotypes.
Methods
Patients with at least two prior first trimester miscarriages and negative standard diagnostic work‐up for RPL and CD underwent HLA‐DQ2/DQ8 genotyping and endometrial biopsy. CE was defined as >5.15 CD 138 positive plasma cells per 10 mm 2 (1/high‐power field). Increased uNK levels were defined as >4.5%.
Results
In this study, a total of 197 idiopathic RPL patients were included: 92 were HLA‐DQ2/DQ8‐high risk and 105 were HLA‐DQ2/DQ8‐low risk. While the prevalence of CE was not significantly different, increased uNK density was significantly more frequent in HLA‐DQ2/DQ8 high‐risk patients compared to HLA‐DQ2/DQ8 low‐risk patients (50% vs. 29.7%, p = 0.017). In multiple regression analysis, HLA‐DQ2/DQ8 risk was independently associated with high uNK cell levels (aOR 2.25, 95%CI 1.01–5.02, p = 0.049).
Conclusions
These findings suggest that HLA‐mediated immune mechanisms may increase uNK cell levels, potentially impairing embryo implantation. However, a causal relationship cannot be established.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, Humanitas University, Milan, Italy.
- Unit High risk pregnancy, Humanitas S. Pio X Hospital, Milan, Italy.
- Obstetrics and Gynecology Unit, Department of Experimental, Clinical and Biomedical Sciences, Careggi University Hospital, University of Florence, Florence, Italy.
- Biostatistics Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
ORCID-Profile: Inversetti Annalisa, Zambella Enrica, Bertoli Francesca, Morenghi Emanuela, Di Simone Nicoletta
Zitieren
APA
Annalisa, I., Enrica, Z., Caterina, S., Federica, C., Francesca, B., Emanuela, M., Nicoletta, D. S., & Federico, M. (2026). Chronic Endometritis, Uterine Natural Killer Level and Celiac Disease Predisposition in Idiopathic Recurrent Pregnancy Loss. American Journal of Reproductive Immunology, 96(3). https://doi.org/10.1111/aji.70323
Vancouver
Annalisa I, Enrica Z, Caterina S, Federica C, Francesca B, Emanuela M, et al. Chronic Endometritis, Uterine Natural Killer Level and Celiac Disease Predisposition in Idiopathic Recurrent Pregnancy Loss. American Journal of Reproductive Immunology. 2026;96(3). doi:10.1111/aji.70323
BibTeX
@article{Annalisa2026,
author = {Annalisa, Inversetti and Enrica, Zambella and Caterina, Serena and Federica, Ciliberto and Francesca, Bertoli and Emanuela, Morenghi and Nicoletta, Di Simone and Federico, Mecacci},
title = {Chronic Endometritis, Uterine Natural Killer Level and Celiac Disease Predisposition in Idiopathic Recurrent Pregnancy Loss},
journal = {American Journal of Reproductive Immunology},
year = {2026},
volume = {96},
number = {3},
doi = {10.1111/aji.70323}
}
EUVIMED